Unlocking Novel Targets, Harnessing Emerging Isotopes, & Redefining Drug Design with Advanced Targeting Moieties, Linkers, & Preclinical Dosimetry Insight for Diversified Radiopharmaceutical Pipelines
Radioligand therapy is at a pivotal moment: investment is surging, clinical momentum is building, yet true innovation remains constrained by narrow target strategies and familiar isotope choices.
The 2nd TRP Target Selection & Drug Design Summit is the only meeting focused on next-generation RLT design - uniting the experts who are redefining how we select targets, match isotopes to biology, minimize toxicity, and accelerate translation to first-in-human success.
Over three days, you’ll uncover the insights, partnerships, and technical breakthroughs needed to move beyond “me-too” drugs and unlock more precise, more durable, and more effective radiopharmaceutical therapies.
While everyone came with a different perspective, there was a real sense that everyone was prepared to discuss the key issues facing our field in a productive manner.
Past Attendee, Director, AstraZeneca
I liked the balance of having both preclinical and clinical speakers that could give an overall picture of the challenges that come with RLTs.
Past Attendees, Senior Scientific Lead, ADME & DMPK, Eli Lilly
From my point of view speakers and companies attending the conference were very well picked. Also, the scope of the conference with a rather selected number of attendants generated a nice, familiar atmosphere. It gave a good possibility to connect with people in the field. Also, the talks were nicely picked and aligned in the conference program.
Past Attendees, Director, Program Management, PentixaPharm
Explore the Full Event Guide
- 100+ Attendees
- 20+ Expert Speakers
- 12+ C-Suite Speakers
- 6+ Hours of Built-In Networking
- 3 Big Pharma Companies
Speakers
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover how the field’s leaders are redefining target selection, isotope pairing, and translational strategy to unlock the next era of radioligand therapy.
Partner With Us
Connect with RLT decision-makers searching for partners in targeting, imaging, radiochemistry, and isotopes to drive faster, safer radiopharmaceutical development.
Join RLT Experts
Join 100+ radiochemists, biologists, drug designers, and R&D leaders advancing next-generation radioligand therapies from discovery through translation.